Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden

被引：0
|
作者：
Åsa Ericsson
Adam Lundqvist
机构：
[1] Novo Nordisk Scandinavia AB,
[2] IHE,undefined
[3] The Swedish Institute for Health Economics,undefined
来源：
Applied Health Economics and Health Policy | 2017年 / 15卷
关键词：
Liraglutide; Insulin Glargine; Basal Insulin; Insulin Aspart; Insulin Detemir;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：237 / 248
页数：11
相关论文
共 50 条
  • [1] Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden
    Ericsson, Asa
    Lundqvist, Adam
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2017, 15 (02) : 237 - 248
  • [2] Fixed-ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin
    Vilsboll, Tina
    Blevins, Thomas C.
    Jodar, Esteban
    Poulter, Neil
    Tentolouris, Nikolaos
    Agner, Bue F. Ross
    Lehmann, Lucine
    Leiter, Lawrence A.
    DIABETES OBESITY & METABOLISM, 2019, 21 (06): : 1506 - 1512
  • [3] Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes
    Gough, Stephen C. L.
    Jain, Rajeev
    Woo, Vincent C.
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2016, 11 (01) : 7 - 19
  • [4] Efficacy and safety of fixed-ratio combination of insulin degludec and liraglutide (IDegLira) for the treatment of type 2 diabetes
    Vedtofte, Louise
    Knop, Filip K.
    Vilsboll, Tina
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (03) : 387 - 396
  • [5] Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira)
    Buse, John B.
    Vilsboll, Tina
    Thurman, Jerry
    Blevins, Thomas C.
    Langbakke, Irene H.
    Bottcher, Susanne G.
    Rodbard, Helena W.
    DIABETES CARE, 2014, 37 (11) : 2926 - 2933
  • [6] Fixed Combination of Insulin Degludec and Liraglutide in Type 2 Diabetes Treatment
    Jaecke, E.
    Wilhelm, B.
    Kaiser, M.
    DIABETES STOFFWECHSEL UND HERZ, 2015, 24 (06): : 387 - 395
  • [7] IDegLira, a combination of insulin degludec and liraglutide, is efficacious across the range of disease progression in Type 2 diabetes
    Gough, S. C. L.
    Rodbard, H. W.
    Woo, V. C.
    Langbakke, I. H.
    Korsholm, L.
    Vilsboll, T.
    DIABETIC MEDICINE, 2015, 32 : 75 - 75
  • [8] Insulin degludec/liraglutide (IDegLira) improves patient-reported outcomes in subjects with type 2 diabetes uncontrolled on insulin glargine plus metformin: DUALV
    Lingvay, I.
    Manghi, F. C. Perez
    Garcia-Hernandez, P. A.
    Norwood, P.
    Jarlov, H.
    Kongso, J. H.
    Brod, M.
    DIABETOLOGIA, 2015, 58 : S400 - S400
  • [9] Cost-effectiveness analysis of insulin degludec/liraglutide (IDegLira) vs other basal insulin intensification strategies in Type 2 diabetes patients uncontrolled on basal insulin in a UK setting
    Davies, M.
    McEwan, P.
    Glah, D.
    Chubb, B.
    Konidaris, G.
    Iversen, P.
    DIABETIC MEDICINE, 2016, 33 : 155 - 155
  • [10] Novel combination of insulin degludec and liraglutide (IDegLira) is efficacious across the range of disease progression in type 2 diabetes
    Rodbard, H. W.
    Buse, J. B.
    Woo, V. C.
    Vilsboll, T.
    Langbakke, I.
    Korsholm, L.
    Gough, S.
    DIABETOLOGIA, 2014, 57 : S338 - S339
12345